{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:44Z","timestamp":1787024624599,"version":"build-2736575974"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.2169\/internalmedicine.5839-25","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:10:16Z","timestamp":1753308616000},"page":"582-586","source":"Crossref","is-referenced-by-count":4,"title":["Development of Hypothyroidism in a Patient with ATTRv Amyloidosis Following Patisiran Administration"],"prefix":"10.2169","volume":"65","author":[{"given":"Hisatsugu","family":"Tachibana","sequence":"first","affiliation":[{"name":"Department of Neurology, Takatsuki General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Takatsuki General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Adams D, Gonzalez-Duarte A, O&apos;Riordan WD, et al. Patisiran, an RNAi, therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379: 11-21, 2018."},{"key":"2","unstructured":"2. Usuzaka M, Ishibashi H, Yureneva E, Boyle K. Early post-marketing phase vigilance in patients with transthyretin-type familial amyloidosis with polyneuropathy treated with vutrisiran sodium (AMVUTTRA). Shindan to Shinyaku (Med Cons New-Remed) 61: 7-14, 2024 (in Japanese)."},{"key":"3","unstructured":"3. Onpattro<sup>\u00ae<\/sup> attached document (in Japanese). Alnylam Japan. Onpattro<sup>\u00ae<\/sup>intravenous infusion 2 mg\/mL attached document 2nd edition (July 7th 2023)."},{"key":"4","unstructured":"4. Amvuttra<sup>\u00ae<\/sup> attached document (in Japanese). Alnylam Japan. Amvuttra<sup>\u00ae<\/sup>subcutaneos injection 25 mg syringe attached document 1st edition (November 26th 2022)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 10: 158-173, 2005.","DOI":"10.1111\/j.1085-9489.2005.0010206.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 87: 1196-1201, 2012.","DOI":"10.1016\/j.mayocp.2012.10.013"},{"key":"7","unstructured":"7. PMDA patisiran natrium review reports (in Japanese) [Internet]. [cited 2024 May 2]. Available from: https:\/\/www.pmda.go.jp\/drugs\/2019\/P20190717001\/112773000_30100AMX00012_A100_2.pdf"},{"key":"8","unstructured":"8. PMDA vutrisiran natrium review reports (in Japanese) [Internet]. [cited 2024 May 2]. Available from: https:\/\/www.pmda.go.jp\/drugs\/2022\/P20221005002\/112773000_30400AMX00432_A100_1.pdf"},{"key":"9","unstructured":"9. PMDA patisiran natrium applicant explains (in Japanese) [Internet]. [cited 2024 May 2]. Available from: https:\/\/www.pmda.go.jp\/drugs\/2019\/P20190717001\/index.html"},{"key":"10","unstructured":"10. Suzuki S. Thyroid hormone transport: a journey from thyroid gland to targeted nuclear receptors. Shinshu Igaku Zasshi (Shinshu Med J) 59: 403-410, 2011 (in Japanese)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mimoto MS, Refetoff S. Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations. J Endocrinol Invest 43: 31-41, 2020.","DOI":"10.1007\/s40618-019-01084-9"},{"key":"12","unstructured":"12. MHLW Grants-in-Aid for Scientific Research on Intractable Diseases, Research Group for Investigation of Amyloidosis. Amyloidosis Clinical Practice Guidelines 2010 [Internet]. [cited 2024 Nov 1]. Available from: http:\/\/amyloidosis-research-committee.jp\/wp-content\/uploads\/2018\/02\/guideline2010.pdf"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Huang G, Ueda M, Tasaki M, et al. Clinicopathological and iochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation. Amyloid 24: 24-29, 2017.","DOI":"10.1080\/13506129.2016.1276440"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J 13: 55-59, 2017.","DOI":"10.14797\/mdcj-13-2-55"},{"key":"15","unstructured":"15. Kageyama Y, Saitoh T. A case of hypothyroidism associated with immunoglobulin-linked macro creatine kinase. Iryo (Jpn J Natl Serv) 50: 844-848, 1996 (in Japanese)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ono R, Okada S, Aoki K, Kato K, Iwahana T, Kobayashi Y. Transthyretin amyloidosis with macro-creatine kinase. BMJ Case Rep 15: e251209, 2022.","DOI":"10.1136\/bcr-2022-251209"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Doran GR, Wilkinson JH. The origin of the elevated activities of creatine kinase and other enzymes in the sera of patients with myxedema. Clin Chim Acta 62: 203-211, 1975.","DOI":"10.1016\/0009-8981(75)90229-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/4\/65_5839-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:43:06Z","timestamp":1771645386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/4\/65_5839-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5839-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"article-number":"5839-25"}}